OBiO Tech(SH:688238) Xin Lang Cai Jing·2025-09-26 01:39Group 1 - The core viewpoint of the news highlights the recent trading performance of He Yuan Biological Technology, indicating a decline in stock price and net financing outflow on September 25, 2023 [1] - On September 25, He Yuan Biological experienced a stock price drop of 1.84%, with a trading volume of 167 million yuan [1] - The financing data shows that on the same day, the company had a financing buy-in amount of 19.10 million yuan and a financing repayment of 23.14 million yuan, resulting in a net financing outflow of 4.04 million yuan [1] Group 2 - As of September 25, the total balance of margin trading for He Yuan Biological was 144 million yuan, which accounts for 2.80% of its market capitalization [1] - The current financing balance is below the 20th percentile level over the past year, indicating a low position [1] - In terms of securities lending, there were no shares repaid or sold on September 25, with the lending balance also at zero, suggesting a high position relative to the 80th percentile level over the past year [1] Group 3 - He Yuan Biological Technology, established on March 5, 2013, and listed on March 22, 2022, specializes in providing CRO services for gene therapy and CDMO services for drug development [2] - The company's revenue composition includes 54.75% from cell and gene therapy CDMO services, 33.96% from CRO services, 10.28% from bioreagents and other services, and 1.02% from regenerative medicine services [2] - For the first half of 2025, He Yuan Biological reported a revenue of 120 million yuan, reflecting a year-on-year growth of 6.01%, while the net profit attributable to shareholders was -105 million yuan, showing a year-on-year increase of 7.74% [2]